Mark Meyer
Family Medicine · Tallmadge, OHNPI 1306836002
Payments from drug & device makers
Across 108 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$225
- AbbVie$178
- Bayer$145
- Novo Nordisk$127
- Amarin Pharma, Inc.$113
- Boehringer Ingelheim$93
- plus $712 from 22 others
What the payments were for
- Food & beverage$1,57399%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $225 |
| AbbVie(2 entities) | 13 | $178 |
| Bayer | 11 | $145 |
| Novo Nordisk | 8 | $127 |
| Amarin Pharma, Inc. | 7 | $113 |
| Boehringer Ingelheim | 6 | $93 |
| Novartis | 6 | $89 |
| Pfizer | 5 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lilly USA, LLC | 4 | $52 |
| AstraZeneca | 4 | $51 |
| Lundbeck LLC | 2 | $50 |
| Astellas Pharma US Inc | 3 | $49 |
| Merck | 3 | $39 |
| Johnson & Johnson | 3 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$1,592 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $7,900 |
| Rosuvastatin Calcium | 12 | $376 |
| Digoxin | 14 | $326 |
| Donepezil Hcl | 13 | $181 |
| Metoprolol Tartrate | 13 | $125 |
| Amoxicillin | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $74 | $7,90017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Tallmadge
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.